CN110234639A - 替吡法尼的晶型及其制备方法及药物组合物 - Google Patents
替吡法尼的晶型及其制备方法及药物组合物 Download PDFInfo
- Publication number
- CN110234639A CN110234639A CN201680092058.0A CN201680092058A CN110234639A CN 110234639 A CN110234639 A CN 110234639A CN 201680092058 A CN201680092058 A CN 201680092058A CN 110234639 A CN110234639 A CN 110234639A
- Authority
- CN
- China
- Prior art keywords
- crystal form
- buddhist nun
- method buddhist
- pyrrole method
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
一种替吡法尼的晶型，与已知的替吡法尼固体形式相比，该替吡法尼晶型在结晶度、吸湿性、形貌、晶型稳定性和化学稳定性等方面具有优势。还涉及替吡法尼晶型的制备方法，其药物组合物及其在制备用于治疗和/或预防细胞异常生长疾病的用途。
Description
PCT国内申请，说明书已公开。
Claims (20)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/108970 WO2018103027A1 (zh) | 2016-12-08 | 2016-12-08 | 替吡法尼的晶型及其制备方法及药物组合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110234639A true CN110234639A (zh) | 2019-09-13 |
Family
ID=62490628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680092058.0A Pending CN110234639A (zh) | 2016-12-08 | 2016-12-08 | 替吡法尼的晶型及其制备方法及药物组合物 |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US10954210B2 (zh) |
| CN (1) | CN110234639A (zh) |
| WO (1) | WO2018103027A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10954210B2 (en) | 2016-12-08 | 2021-03-23 | Hangzhou Solipharma Co., Ltd. | Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof |
| WO2023141082A1 (en) | 2022-01-20 | 2023-07-27 | Teva Czech Industries S.R.O. | Solid state forms of tipifarnib and process for preparation thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1203598A (zh) * | 1995-12-08 | 1998-12-30 | 詹森药业有限公司 | 抑制法呢基蛋白质转移酶的(咪唑－5－基)甲基－2－喹啉酮衍生物 |
| CN1496363A (zh) * | 2001-03-12 | 2004-05-12 | ղɭҩҵ����˾ | 咪唑化合物的制备方法 |
| WO2005105784A1 (en) * | 2004-05-03 | 2005-11-10 | Janssen Pharmaceutica N.V. | Diastereoselective synthesis process for the preparation of imidazole compounds |
| CN104736569A (zh) * | 2012-01-12 | 2015-06-24 | 耶鲁大学 | 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法 |
| CN105616361A (zh) * | 2014-10-30 | 2016-06-01 | 复旦大学 | 一种注射用替尼类药物白蛋白纳米制剂的制备方法 |
| CN106176584A (zh) * | 2005-10-14 | 2016-12-07 | 詹森药业有限公司 | 用于静脉施用的替比法尼制剂 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10954210B2 (en) | 2016-12-08 | 2021-03-23 | Hangzhou Solipharma Co., Ltd. | Crystal form of tipifarnib and preparation method and pharmaceutical composition thereof |
-
2016
- 2016-12-08 US US16/467,515 patent/US10954210B2/en active Active
- 2016-12-08 CN CN201680092058.0A patent/CN110234639A/zh active Pending
- 2016-12-08 WO PCT/CN2016/108970 patent/WO2018103027A1/zh active Application Filing
-
2020
- 2020-12-23 US US17/133,508 patent/US11639341B2/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1203598A (zh) * | 1995-12-08 | 1998-12-30 | 詹森药业有限公司 | 抑制法呢基蛋白质转移酶的(咪唑－5－基)甲基－2－喹啉酮衍生物 |
| CN1496363A (zh) * | 2001-03-12 | 2004-05-12 | ղɭҩҵ����˾ | 咪唑化合物的制备方法 |
| WO2005105784A1 (en) * | 2004-05-03 | 2005-11-10 | Janssen Pharmaceutica N.V. | Diastereoselective synthesis process for the preparation of imidazole compounds |
| CN106176584A (zh) * | 2005-10-14 | 2016-12-07 | 詹森药业有限公司 | 用于静脉施用的替比法尼制剂 |
| CN104736569A (zh) * | 2012-01-12 | 2015-06-24 | 耶鲁大学 | 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法 |
| CN105616361A (zh) * | 2014-10-30 | 2016-06-01 | 复旦大学 | 一种注射用替尼类药物白蛋白纳米制剂的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US10954210B2 (en) | 2021-03-23 |
| WO2018103027A1 (zh) | 2018-06-14 |
| US11639341B2 (en) | 2023-05-02 |
| US20190345134A1 (en) | 2019-11-14 |
| US20210214335A1 (en) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110577536B (zh) | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 | |
| KR20220005631A (ko) | C-met 조절제 약제학적 조성물 | |
| CN112142679B (zh) | 一种吉非替尼与香草酸共晶甲醇溶剂合物及其制备方法 | |
| CN112047892B (zh) | 一种吉非替尼与3-羟基苯甲酸共晶体 | |
| CN110577533A (zh) | 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用 | |
| TWI669304B (zh) | Ｃ－Ｍｅｔ抑制劑結晶型游離鹼或其結晶型酸式鹽及其製備方法和應用 | |
| KR20170057441A (ko) | Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법 | |
| WO2019019959A1 (zh) | 瑞博西尼的单琥珀酸盐晶型及其制备方法和用途 | |
| KR102522895B1 (ko) | Jak 키나아제 억제제 바이설페이트의 결정형 및 이의 제조방법 | |
| CN106279127B (zh) | 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物 | |
| WO2016155670A1 (zh) | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 | |
| WO2018103726A1 (zh) | 一种溴结构域蛋白抑制剂药物的晶型及其制备方法和用途 | |
| US9884856B2 (en) | Crystal form of Dabrafenib mesylate and preparation method thereof | |
| US11639341B2 (en) | Crystal form of tipifarnib and method of treatment thereof | |
| CN104918937A (zh) | 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途 | |
| EP3919485A1 (en) | Crystals of quinoline derivatives | |
| WO2018106657A1 (en) | Compositions and methods related to pyridinoylpiperidine 5-ht1f agonists | |
| US10544129B2 (en) | Crystalline forms of AP26113, and preparation method thereof | |
| AU2020240301A1 (en) | Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridine-2-yl)-5-fluoro-4-(3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine and its salts, and preparation methods and therapeutic uses thereof | |
| CN112778290B (zh) | 一种s1p1受体激动剂的加成盐及其晶型和药物组合物 | |
| CN105367492B (zh) | 他喹莫德的晶型及其制备方法、其药物组合物和用途 | |
| WO2022253261A1 (zh) | Lazertinib甲磺酸盐的水合物晶型及其制备方法和用途 | |
| CN111848580B (zh) | 含1,2,4-三嗪-3,5-二酮的喹啉类化合物的晶型及其制备方法和应用 | |
| CN109280035B (zh) | 奥扎莫德的多晶型及其制备方法 | |
| CN106279192B (zh) | 一种喹唑啉衍生物盐酸盐的结晶多晶型物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190913 |